Axatilimab clinical trials
Also written SNDX-6352 and INCA034176.
How each study uses axatilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the axatilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Aug 2024 · NIKTIMVO · BLA 761411 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2025 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 14
Incyte Corporation (6) · Syndax Pharmaceuticals (5) · Northside Hospital, Inc. (2) · Stephen Shiao (2) · M.D. Anderson Cancer Center (2) · Incyte Biosciences Japan GK (1) · University of Utah (1) · Medical College of Wisconsin (1)
Often tested with
Tested in the same studies.
Ruxolitinib (2) · Adrenal Cortex Hormones (1) · Decitabine (1) · Venetoclax (1) · Cyclophosphamide (1) · Retifanlimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 1 in phase 3
Studies that test axatilimab, phase 3 first.
- Sep 2027A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePhase 3 · Incyte Corporation
- Dec 2026Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaPhase 2 · University of Utah
- Dec 2026Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationPhase 2 · Stephen Shiao
- Jan 2027A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDPhase 1/2 · Incyte Corporation
- Apr 2027Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsPhase 1/2 · OHSU Knight Cancer Institute
- May 2027Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerPhase 1 · Dana-Farber Cancer Institute
- Oct 2027Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaPhase 1/2 · Uma Borate
Studies
Open first, then newest update. How each study uses axatilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationRecruitingPhase 2Stephen ShiaoNCT05491226Written as Axatilimab
- ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationRecruitingPhase 2Stephen ShiaoNCT07015853Written as Axatilimab
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseRecruitingPhase 3Incyte CorporationNCT06585774Written as INCA034176
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)RecruitingPhase 2Incyte CorporationNCT07124078Written as INCA034176
- Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaRecruitingPhase 1/2Uma BorateNCT06523556Written as Axatilimab
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingPhase 1Northside Hospital, Inc.NCT07511062Written as Axatilimab
- Axatilimab + CAR-T for High-Risk LymphomaNot yet recruitingPhase 1Northside Hospital, Inc.NCT07638982Written as Axatilimab
- Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07128381Written as Axatilimab (SNDX-6352)
- Axatilimab for Sclerotic Chronic Graft-versus-Host DiseaseRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07011810Written as Axatilimab
- CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell TransplantationNot yet recruitingPhase 2Medical College of WisconsinNCT07808112Written as Axatilimab
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingPhase 1Dana-Farber Cancer InstituteNCT06488378Written as Axatilimab
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06320405Written as Axatilimab
- Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host DiseaseRecruitingPhase 2University of MiamiNCT06663722Written as Axatilimab
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)RecruitingPhase 2Syndax PharmaceuticalsNCT04710576Written as Axatilimab
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2Syndax PharmaceuticalsNCT06132256Written as Axatilimab
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseActive, not recruitingPhase 2Incyte CorporationNCT06388564Written as Axatilimab
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host DiseaseActive, not recruitingPhase 3Incyte Biosciences Japan GKNCT06263478Written as INCA034176
- A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)SuspendedPhase 1M.D. Anderson Cancer CenterNCT06959537Written as Axatilimab (SNDX-6352)
- Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS TrialWithdrawnPhase 2Mayo ClinicNCT07349771Written as Axatilimab
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyActive, not recruitingPhase 3Incyte CorporationNCT06821542Written as INCA034176
See all 26 studies that test axatilimab →
Given beside what is tested · 1 — axatilimab is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call axatilimab · ClinicalTrials.gg INT001459
- MeSH (NLM) C000711669axatilimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) R96Z451BMCAXATILIMABConfirmed FDA, NLM
- NCI Thesaurus C155813AxatilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711669 | axatilimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R96Z451BMC | AXATILIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C155813 | Axatilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.